CST (n = 150a) | RSW (n = 157) | ||||||
na | Weighted Mean (95% CI) | n | Weighted Mean (95% CI) | p-Value | OR (95% CI) | p-Value | |
GFR at 1 Year (mL/min/1.73 m2) | 140 | 60.0 (51.7 - 68.3) | 132 | 52.9 (50.1 - 55.8) | 0.11 | ||
Living Donor | 47 | 51.9 (41.1 - 62.7) | 52 | 53.4 (49.4 - 57.3) | 0.80 | ||
Deceased Donor | 93 | 64.1 (53.5 - 74.7) | 80 | 52.7 (48.7 - 56.6) | 0.047 | ||
GFR at 5 Years (mL/min/1.73 m2) | 49 | 50.7 (40.9 - 60.6) | 46 | 52.2 (45.6 - 58.8) | 0.80 | ||
Living Donor | 18 | 42.9 (27.7 - 58.2) | 21 | 53.4 (45.4 - 61.3) | 0.23 | ||
Deceased Donor | 31 | 55.3 (44.1 - 66.5) | 25 | 51.3 (41.1 - 61.4) | 0.59 | ||
na | Weighted% (95% CI) | n | Weighted% (95% CI) | p-Value | |||
Delayed Graft Function | 48 | 32% (23% - 43%) | 16 | 10% (6% - 16%) | <0.001 | 0.15 (0.06 - 0.35) | <0.001 |
Post-Transplant Diabetes Mellitus | 28 | 25% (14% - 41%) | 22 | 22% (15% - 31%) | 0.66 | 0.85 (0.32 - 2.24) | 0.74 |
BK Viremia | 16 | 10% (5% - 20%) | 28 | 18% (13% - 25%) | 0.15 | 2.72 (1.22 - 6.04) | 0.014 |
CMV Viremia | 17 | 11% (5% - 21%) | 37 | 24% (18% - 31%) | 0.04 | 4.14 (1.81 - 9.44) | 0.001 |
Rejection at 1 Year | 15 | 10% (5% - 18%) | 51 | 32% (26% - 40%) | <0.001 | 4.26 (1.99 - 9.13) | <0.001 |
Rejection at 5 Year | 23 | 15% (9% - 25%) | 69 | 44% (36% - 52%) | <0.001 | 4.71 (2.40 - 9.23) | <0.001 |
Biopsy Proven Rejection at 1 Year | 15 | 10% (5% - 18%) | 28 | 18% (13% - 25%) | 0.10 | 2.04 (0.92 - 4.55) | 0.08 |
Biopsy Proven Rejection at 5 Year | 23 | 15% (9% - 25%) | 37 | 24% (18% - 31%) | 0.13 | 1.95 (0.98 - 3.88) | 0.06 |
Types of Rejection (Biopsy-Proven) | <0.001 | ||||||
Grade 1 | 5 | 22% (7% - 50%) | 28 | 70% (54% - 82%) | |||
Grade 2 | 15 | 68% (42% - 87%) | 2 | 5% (1% - 18%) | |||
Grade 3 | 0 | 0% (0% - 3%) | 0 | 0% | |||
Antibody-Mediated Rejection | 2 | 9% (3% - 24%) | 5 | 12% (5% - 27%) | |||
Borderline Rejection | 0 | 0% (0% - 2%) | 5 | 12% (5% - 27%) |